Search

Your search keyword '"Verlaeten, Olivier"' showing total 14 results
Start Over Author "Verlaeten, Olivier"
14 results on '"Verlaeten, Olivier"'

2. Gene activation therapy: From the BLV model to HAM/TSP patients

Author

Lezin, Agnès, Olindo, Stéphane, Belrose, Gildas, Signaté, Aïssatou, Césaire, Raymond, Smadja, Didier, Macallan, Derek, Asquith, Becca, Bangham, Charles, Bouzar, Amel Baya, Gillet, Nicole, Defoiche, Julien, Florins, Arnaud, Verlaeten, Olivier, Burny, Arsène, Willems, Lucas, Lezin, Agnès, Olindo, Stéphane, Belrose, Gildas, Signaté, Aïssatou, Césaire, Raymond, Smadja, Didier, Macallan, Derek, Asquith, Becca, Bangham, Charles, Bouzar, Amel Baya, Gillet, Nicole, Defoiche, Julien, Florins, Arnaud, Verlaeten, Olivier, Burny, Arsène, and Willems, Lucas

Abstract

HTLV-1 (human T-lymphotropic virus type 1) and BLV (bovine leukemia virus) are two related retroviruses infecting CD4+ and B lymphocytes in humans and ruminants, respectively. During infection, the hostpathogen interplay is characterized by very dynamic kinetics resulting in equilibrium between the virus, which attempts to proliferate, and the immune response, which seeks to exert tight control of the virus. A major determinant of disease induction by both viruses is the accumulation of provirus in peripheral blood. In the absence of viral proteins, virus infected cells escape recognition and destruction by the host immune response. We propose a novel therapeutic strategy based on transient activation of viral expression using epigenetic modulators; this exposes infected cells to the immune response and results in significant reductions in proviral loads. In the absence of satisfactory therapies, this viral gene-activation strategy might delay progression, or even be curative, for ?TLV-1 induced myelopathy/tropical spastic paraparesis (HAM/TSP)., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2009

3. Histone deacetylase-mediated transcriptional activation reduces proviral loads in HTLV-1-associated myelopathy/tropical spastic paraparesis patients

Author

Lezin, Agnès, Gillet, Nicolas, Olindo, Stéphane, Signaté, Aïssatou, Grandvaux, Nathalie, Verlaeten, Olivier, Belrose, Gildas, Bittencourt, Marcelo De Carvalho, Hiscott, John, Asquith, Becca, Burny, Arsène, Smadja, Didier, Césaire, Raymond, Willems, Lucas, Lezin, Agnès, Gillet, Nicolas, Olindo, Stéphane, Signaté, Aïssatou, Grandvaux, Nathalie, Verlaeten, Olivier, Belrose, Gildas, Bittencourt, Marcelo De Carvalho, Hiscott, John, Asquith, Becca, Burny, Arsène, Smadja, Didier, Césaire, Raymond, and Willems, Lucas

Abstract

Epigenetic modifications of chromatin may play a role in maintaining viral latency and thus persistence of the human T-lymphotropic virus type 1 (HTLV-1), which is responsible for HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP). A major determinant of disease progression is increased peripheral blood proviral load (PVL), possibly via the accumulation of infected cells in the central nervous system (CNS) creating a damaging inflammatory response. Current therapeutic approaches that focus on reducing either cell proliferation, viral replication, or tissue invasion are still unsatisfactory. Contrasting with these inhibitory strategies, we evaluated the efficacy of a novel approach aimed, paradoxically, at activating viral gene expression to expose virus-positive cells to the host immune response. We used valproate (VPA), a histone deacetylase inhibitor that has been used for decades as a chronic, safe treatment for epileptic disorders. Based on in vitro and in vivo data, we provide evidence that transient activation of the latent viral reservoir causes its collapse, a process that may alleviate the condition of HAM/TSP. This represents the first such approach to treating HAM/TSP, using gene activation therapy to tilt the host-pathogen balance in favor of an existing antiviral response. This trial is registered at http://clinicaltrials.gov/as no. NCT00519181., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2007

4. Chemoresistance to Valproate Treatment of Bovine Leukemia Virus-Infected Sheep; Identification of Improved HDAC Inhibitors

Author

Gillet, Nicolas, primary, Vandermeers, Fabian, additional, de Brogniez, Alix, additional, Florins, Arnaud, additional, Nigro, Annamaria, additional, François, Carole, additional, Bouzar, Amel-Baya, additional, Verlaeten, Olivier, additional, Stern, Eric, additional, Lambert, Didier M., additional, Wouters, Johan, additional, and Willems, Luc, additional

Published
2012
Full Text
View/download PDF

5. Safety of long-term treatment of HAM/TSP patients with valproic acid

Author

Olindo, Stéphane, primary, Belrose, Gildas, additional, Gillet, Nicolas, additional, Rodriguez, Sabrina, additional, Boxus, Mathieu, additional, Verlaeten, Olivier, additional, Asquith, Becca, additional, Bangham, Charles, additional, Signaté, Aïssatou, additional, Smadja, Didier, additional, Lezin, Agnès, additional, Césaire, Raymond, additional, and Willems, Luc, additional

Published
2011
Full Text
View/download PDF

7. Influence of the Dengue Serotype, Previous Dengue Infection, and Plasma Viral Load on Clinical Presentation and Outcome During a Dengue-2 and Dengue-4 Co-Epidemic

Author

Thomas, Laurent, primary, Martial, Jenny, additional, Dussart, Philippe, additional, Plumelle, Yves, additional, Moravie, Victor, additional, Verlaeten, Olivier, additional, Najioullah, Fatiha, additional, Cabié, André, additional, Fonteau, Christiane, additional, Césaire, Raymond, additional, and Kaidomar, Stéphane, additional

Published
2008
Full Text
View/download PDF

8. Histone deacetylase–mediated transcriptional activation reduces proviral loads in HTLV-1–associated myelopathy/tropical spastic paraparesis patients

Author

Lezin, Agnès, primary, Gillet, Nicolas, additional, Olindo, Stéphane, additional, Signaté, Aïssatou, additional, Grandvaux, Nathalie, additional, Verlaeten, Olivier, additional, Belrose, Gildas, additional, de Carvalho Bittencourt, Marcelo, additional, Hiscott, John, additional, Asquith, Becca, additional, Burny, Arsène, additional, Smadja, Didier, additional, Césaire, Raymond, additional, and Willems, Luc, additional

Published
2007
Full Text
View/download PDF

10. Semaphorin CD100 from Activated T Lymphocytes Induces Process Extension Collapse in Oligodendrocytes and Death of Immature Neural Cells

Author

Giraudon, Pascale, primary, Vincent, Peggy, additional, Vuaillat, Carine, additional, Verlaeten, Olivier, additional, Cartier, Luis, additional, Marie-Cardine, Anne, additional, Mutin, Mireille, additional, Bensussan, Armand, additional, Belin, Marie-Françoise, additional, and Boumsell, Laurence, additional

Published
2004
Full Text
View/download PDF

14. Gene activation therapy: from the BLV model to HAM/TSP patients.

Author

Lezin A, Olindo S, Belrose G, Signate A, Cesaire R, Smadja D, Macallan D, Asquith B, Bangham C, Bouzar A, Gillet N, Defoiche J, Florins A, Verlaeten O, Burny A, and Willems L

Subjects
Animals, Humans, Leukemia Virus, Bovine genetics, Paraparesis, Tropical Spastic genetics, Sheep, Gene Expression, Genetic Therapy, Leukemia Virus, Bovine physiology, Models, Biological, Paraparesis, Tropical Spastic therapy
Abstract

HTLV-1 (human T-lymphotropic virus type 1) and BLV (bovine leukemia virus) are two related retroviruses infecting CD4+ and B lymphocytes in humans and ruminants, respectively. During infection, the host-pathogen interplay is characterized by very dynamic kinetics resulting in equilibrium between the virus, which attempts to proliferate, and the immune response, which seeks to exert tight control of the virus. A major determinant of disease induction by both viruses is the accumulation of provirus in peripheral blood. In the absence of viral proteins, virus infected cells escape recognition and destruction by the host immune response. We propose a novel therapeutic strategy based on transient activation of viral expression using epigenetic modulators; this exposes infected cells to the immune response and results in significant reductions in proviral loads. In the absence of satisfactory therapies, this viral gene-activation strategy might delay progression, or even be curative, for HTLV-1 induced myelopathy / tropical spastic paraparesis (HAM/TSP).

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results